PCR Market for Life Sciences and Diagnostics (qPCR & dPCR, TMA and Other NAAT)

 
   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990



Published Apr 12, 2017 | 427 Pages | Pub ID: KLI15318010

PCR Testing Market for Life Sciences and Diagnostics (qPCR, dPCR and other NAAT)

Polymerase chain reaction (PCR) technology was the first of what are now many nucleic acid amplification testing (NAAT) methods that have been developed and commercialized. PCR technology is widely used for both life science (research) market and diagnostic applications, with many companies active in these fields. Real-time PCR (qPCR) has become the most widely used DNA amplification method today. PCR Testing Market for Life Sciences and Diagnostics (qPCR, dPCR and other NAAT) examines the markets for life science and clinical applications of PCR and Other NAAT technologies.

The report contains in-depth information on PCR (qPCR, dPCR and other NAAT), breaking the market opportunity down by type of NAAT, instruments versus consumables, market segment, disease indication, and type of infection, including the following data points:
  • Nucleic Acid Amplification Test Market, Worldwide, 2016 and 2021 (All NAATs: Life Science NAAT Market, Clinical NAAT Market, Other NAAT Market, Total NAAT Market)
  • Life Science PCR Market, Instruments versus Consumables, Worldwide, 2016 and 2021 (Reagents/Consumables, Instruments, Software & Services, Total life science PCR market)
  • Life Science PCR Market, by Type of PCR, Worldwide, 2016 (%) (qPCR, dPCR)
  • Life Science PCR Market, by Type of PCR, Worldwide, 2021 (%) (qPCR, dPCR)
  • Diagnostic PCR and Other NAAT Market by Disease Indication, Worldwide, 2016 and 2021 (Infectious Disease, Oncology, Genetic Testing, Transplantation Diagnostics, Other; Total Diagnostics Segment; Blood Screening; Total Clinical NAAT Market)
  • Diagnostic PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2016 (%) (PCR, TMA, Other NAAT)
  • Diagnostic PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2021 (%) (PCR, TMA, Other NAAT)
  • Diagnostic Infectious Disease PCR and Other NAAT Market by Type of Infection, Worldwide, 2016 and 2021 (Hepatitis, HIV, Healthcare Acquired Infections and Sepsis, Respiratory Pathogens, Sexually Transmitted Diseases and Women’s Health, Tuberculosis, Other, Total)
  • Diagnostic Oncology PCR and Other NAAT Market (Screening, Diagnosis/Prognosis/Personalized Medicine/Monitoring) Worldwide, 2016 and 2021 (Cancer screening market, Cancer diagnostics market, Total cancer NAAT market)
  • Diagnostic PCR and Other NAAT Genetic Testing Market by Market Segment, Worldwide, 2016 and 2021 (Inherited Diseases, Thrombophilia, Pharmacogenomics, Total genetic testing market)
The PCR (qPCR, dPCR and other NAAT) market coverage is regional as well, providing the following geographic breakouts for the infectious disease PCR market, PCR oncology or cancer diagnostics, and PCR genetic testing segment, among others:
  • Life Science PCR Market, by Geographical Distribution (%) (U.S., Europe, Japan, ROW)
  • Clinical PCR and Other NAAT Market by Geographical Region, Worldwide, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, Total Clinical NAAT Market)
  • Diagnostic Infectious Disease PCR and Other NAAT Market, Worldwide by Geographical Region, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, Total - World)
  • Diagnostic Oncology PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, World)
  • Diagnostic Inherited Disease PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Rest of World, World)
  • Diagnostic Transplantation Diagnostics PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Japan, Rest of World, World)
  • PCR and Other NAAT Blood Screening Market, by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, Total)
Beyond these market size and regional estimates and forecasts for both the life science (research) and diagnostic uses of PCR, the report provides an overview of PCR and other NAAT technologies, in addition to discussion of applications of NAAT in life science and clinical diagnostics.

PCR Testing Market for Life Sciences and Diagnostics (qPCR, dPCR and other NAAT) also includes financial information on deals made by PCR and other NAAT companies, including investments and financing agreements, acquisitions, collaborations, and other agreements

Market drivers and challenges in the nucleic acid amplification test market are discussed as well. Issues of growth, competition, market opportunities, regulation, reimbursement, and prospects for the future are reviewed. Some NAAT-based tests are laboratory developed tests (LDTs); the implications of this are discussed. The clinical NAAT market is driven by the need for the information generated by testing. Market changes such as the emergence of new pathogens (such as the Zika virus), or the increasing problem of antibiotic resistance, or other changes are driving the need for specific tests.

The report contains profiles of companies in the market, reflecting the wide range NAAT products and applications in both the life science PCR market and the clinical PCR market. A wide range of industry players is examined, including companies marketing NAAT instruments and/or consumables to the life science research market, companies developing or marketing in vitro diagnostic (IVD) NAAT platforms and tests to clinical laboratories, diagnostic companies offering NAAT tests as a service via their own CLIA-certified laboratory, companies developing or marketing NAAT platforms and tests for rapid point-of-care or near-patient testing, companies developing or marketing PCR-based sample/library preparation products or test panels for DNA sequencing, companies developing or marketing mass spectrometry platforms that include PCR amplification before analysis by mass spectrometry, and companies developing or marketing other technology platforms that include PCR amplification as an initial or early step. Such companies include:
  • Abbott Laboratories
  • Agena Bioscience, Inc.
  • Agilent Technologies, Inc.
  • Alere, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Asuragen, Inc.
  • Atlas Genetics, Ltd.
  • Autogenomics, Inc.
  • Beckman Coulter, Inc. (A Danaher Corporation Company)
  • Becton, Dickinson And Company (BD)
  • Biocartis Group NV
  • Biofire Diagnostics, LLC. (Acquired by bioMérieux)
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Canon Biomedical
  • Cepheid (A Danaher Company)
  • Curetis
  • Diasorin S.p.A.
  • Eiken Chemical Co., Ltd.
  • Elitechgroup
  • Genepoc, Inc.
  • Genmark Diagnostics, Inc.
  • Genomic Health, Inc.
  • Grifols
  • Hologic, Inc.
  • Invivoscribe Technologies, Inc.
  • Janssen Diagnostics (Division of Janssen Pharmaceutica NV)
  • Luminex Corporation
  • Mast Group
  • Meridian Bioscience, Inc.
  • Multiplicom NV (Part of Agilent Technologies)
  • Qiagen N.V.
  • Quandx, Inc.
  • Quantumdx Group
  • Quidel, Inc.
  • Qvella Corporation
  • RainDance Technologies, Inc. (Acquired by Bio-Rad Laboratories)
  • Roche
  • Siemens Healthineers
  • Spartan Bioscience, Inc.
  • Stat-Diagnostica
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.

  • $213.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included

    • $93.00 Included
      •   PCR and Other NAAT Market, Worldwide, 2016 and 2021 [All NAATs - Life Science and Clinical Markets] (in millions USD)
    •  
      $93.00 Included

  • $224.00 Included

    • $187.00 Included
      •  
        $93.00 Included
      •  
        $93.00 Included
      •  
        $93.00 Included
    •  
      $93.00 Included

  • $1,448.00 Included

    • $321.00 Included
      •  
        $93.00 Included

      • $93.00 Included
        •   Selected Companies with Digital PCR Technology (For Research and/or Diagnostic Tests)

      • $124.00 Included
        •   Selected Companies with Multiplex PCR Technology [Note: This is not a comprehensive list of all companies with multiplex PCR technology/tests.]

      • $93.00 Included
        •   Selected Companies with Innovative PCR-Based Methods

    • $135.00 Included
      •  
        $93.00 Included

      • $99.00 Included
        •   Companies with Other Nucleic Acid Amplification Test Methods

    • $728.00 Included
      •   Selected Companies Marketing PCR Instruments/Reagents to the Life Sciences Market
      •   Selected Companies Marketing NAAT Platforms/Tests to Clinical Laboratories
      •   Selected Companies with NAAT Platforms and Tests for Decentralized Testing or Point-of-Care Settings

    • $263.00 Included

      • $93.00 Included
        •   Examples of Companies Using PCR during Sample Prep before DNA Sequencing

      • $93.00 Included
        •   Selected Companies Developing Platforms That Use PCR before Analysis by Mass Spectrometry

      • $98.00 Included
        •   Selected Companies Using PCR with Other Technologies (Beyond Sequencing and Mass Spectrometry)

  • $4,020.00 Included
    •  
      $93.00 Included

    • $1,813.00 Included

      • $1,101.00 Included
        •   Selected Common Microorganisms Detected by Clinical NAAT Tests
        •   Selected Companies Marketing PCR/NAAT Infectious Disease Tests (Single or Limited Number of Analytes)
        •   Selected Companies Marketing PCR/NAAT Syndromic Tests/Panels for Infectious Diseases

      • $363.00 Included
        •   Selected Companies Marketing PCR/NAAT-Based Antibiotic Resistance/Susceptibility Tests

      • $349.00 Included
        •   Selected Companies Marketing Rapid Near-Patient/Point-of-Care PCR/NAAT Infectious Disease Tests
        •   CLIA Waived NAAT Infectious Disease Tests

    • $959.00 Included
      •  
        $93.00 Included

      • $205.00 Included
        •   Selected Companies Developing/Marketing Diagnostic Tests for HPV
        •   Selected Companies Developing/Marketing PCR/NAAT Tests for Cancer Screening (Not including HPV Tests for Cervical Cancer)

      • $676.00 Included
        •   Selected Companies Developing/Marketing PCR/NAAT Tests for Diagnosis/Prognosis/Predicting Response to Cancer Therapy
        •   Selected PCR/NAAT Based, FDA Cleared/Approved Companion Diagnostic Tests

    • $136.00 Included
      •   Selected Companies Developing/Marketing PCR Tests for Risk of Thrombophilia
      •   Selected Companies Developing/Marketing PCR Warfarin Sensitivity Tests
      •   Selected Companies Developing/Marketing Other PCR-Based Cardiovascular Tests

    • $935.00 Included

      • $150.00 Included
        •   Selected Companies Developing/Marketing PCR Tests for Risk of Inherited (Genetic) Disorders

      • $612.00 Included
        •   Pharmacogenomic Biomarkers in Drug Labeling
        •   Selected Companies Developing/Marketing PCR Tests for Pharmacogenomics (Drug Metabolism)

      • $173.00 Included
        •   Selected Companies Developing/Marketing PCR Tests for HLA Typing

    • $113.00 Included
      •   Selected Companies Developing/Marketing PCR Tests for Other Clinical Applications

    • $123.00 Included
      •   Selected Companies Developing/Marketing PCR Tests Transfusion Medicine
    •  
      $93.00 Included

  • $2,282.00 Included

    • $641.00 Included
      •   Selected Investment and Financing Agreements in NAAT Companies

    • $409.00 Included
      •   Selected Acquisitions of NAAT Companies

    • $716.00 Included
      •   Selected Agreements between NAAT Companies and Other Companies [Not Including Pharmaceutical Companies]

    • $316.00 Included
      •   Selected Agreements between NAAT Companies and Pharmaceutical or Biopharmaceutical Companies

    • $184.00 Included
      •   Selected NAAT Company Agreements with Academic or Other Non-Profit Organizations

  • $581.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included

    • $93.00 Included
      •  
        $93.00 Included
      •  
        $93.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included

    • $93.00 Included
      •   Trends in the Polymerase Chain Reaction/Nucleic Acid Amplification Test Market

  • $975.00 Included

    • $93.00 Included
      •   Nucleic Acid Amplification Test Market, Worldwide, 2016 and 2021 [All NAATs -Life Science and Clinical Markets] (in millions USD)

    • $169.00 Included

      • $93.00 Included
        •   Growth of the Life Science PCR Market (1990 - 2016) [# Abstracts Found per Year in PubMed search for "'polymerase chain reaction' or pcr"] (Accessed March 27, 2017)

      • $93.00 Included
        •   Life Science PCR Market, Instruments versus Consumables, Worldwide, 2016 and 2021 (in millions USD)

      • $93.00 Included
        •   Life Science PCR Market, by Geographical Distribution

      • $93.00 Included
        •   Life Science PCR Market, by Type of PCR, Worldwide, 2016
        •   Life Science PCR Market, by Type of PCR, Worldwide, 2021

    • $114.00 Included
      •   Clinical PCR and Other NAAT Market by Disease Indication, Worldwide, 2016 and 2021 (in millions USD)
      •   Clinical PCR and Other NAAT Market by Geographical Region, Worldwide, 2016 and 2021 (in millions USD)
      •   Clinical PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2016
      •   Clinical PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2021

    • $147.00 Included
      •   Diagnostic Infectious Disease PCR and Other NAAT Market by Type of Infection, Worldwide, 2016 and 2021 (in millions USD)
      •   Diagnostic Infectious Disease PCR and Other NAAT Market, Worldwide by Geographical Region, 2016 and 2021 (in millions USD)

    • $157.00 Included
      •  
        $93.00 Included

      • $93.00 Included
        •   Diagnostic Oncology PCR and Other NAAT Market (Screening, Diagnosis/Prognosis/Personalized Medicine/Monitoring) Worldwide, 2016 and 2021 (in millions USD)
        •   Diagnostic Oncology PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD)

    • $160.00 Included
      •   Diagnostic PCR and Other NAAT Genetic Testing Market by Market Segment (Thrombophilia, Inherited Diseases, Pharmacogenomics) Worldwide, 2016 and 2021(in millions USD)
      •   Diagnostic Inherited Disease PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD)

    • $93.00 Included
      •   Diagnostic Transplantation Diagnostics PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD)

    • $93.00 Included
      •   PCR and Other NAAT Blood Screening Market, by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD)

  • $4,020.00 Included

    • $200.00 Included

      • $93.00 Included
        •   Abbott Revenues (2013 to 2016)
      •  
        $154.00 Included
    •  
      $135.00 Included

    • $93.00 Included

      • $93.00 Included
        •   Agilent Technologies Revenues (2014, 2015, 2016)
      •  
        $93.00 Included

    • $188.00 Included

      • $93.00 Included
        •   Alere Inc. Revenues (2014, 2015, and first three quarters of 2016)
      •  
        $138.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included
    •  
      $152.00 Included
    •  
      $139.00 Included

    • $93.00 Included
      •  
        $93.00 Included
      •  
        $93.00 Included

    • $157.00 Included

      • $93.00 Included
        •   Becton Dickinson Revenues (2014 to 2016)
      •  
        $134.00 Included

    • $427.00 Included

      • $93.00 Included
        •   Biocartis Revenues (2014 to 2016)
      •  
        $405.00 Included

    • $124.00 Included
      •  
        $93.00 Included
      •  
        $93.00 Included

    • $176.00 Included

      • $93.00 Included
        •   bioMérieux Revenues (2013 to 2016)
        •   bioMérieux Revenues (2013, 2014, 2015, 3 quarters of 2016)
      •  
        $145.00 Included

    • $93.00 Included

      • $93.00 Included
        •   Bio-Rad Laboratories Net Sales (2014 to 2016)
      •  
        $93.00 Included

    • $116.00 Included

      • $93.00 Included
        •   Bruker Corporation Revenues (2013 - 2016)
      •  
        $106.00 Included
    •  
      $93.00 Included

    • $114.00 Included

      • $93.00 Included
        •   Cepheid Revenues (2013 - 2015)
      •  
        $93.00 Included

    • $198.00 Included

      • $93.00 Included
        •   Curetis Revenues (2014, 2015, and first three quarters of 2016)
      •  
        $185.00 Included

    • $181.00 Included

      • $93.00 Included
        •   DiaSorin Revenues (2015 and 2016)
      •  
        $174.00 Included

    • $173.00 Included

      • $93.00 Included
        •   Eiken Chemical Co., Ltd. Revenues (FY2014 - FT 2016)
      •  
        $154.00 Included
    •  
      $102.00 Included
    •  
      $93.00 Included

    • $93.00 Included

      • $93.00 Included
        •   GenMark Diagnostics Revenue (2013-2016)
      •  
        $93.00 Included

    • $93.00 Included

      • $93.00 Included
        •   Genomic Health Revenues (2014 to 2016)
      •  
        $93.00 Included

    • $99.00 Included

      • $93.00 Included
        •   Grifols Revenues (2015 and 2016)
      •  
        $94.00 Included

    • $125.00 Included

      • $93.00 Included
        •   Hologic Revenues (FY2014 - FY 2016)
      •  
        $102.00 Included
    •  
      $100.00 Included
    •  
      $93.00 Included

    • $174.00 Included

      • $93.00 Included
        •   Luminex Corporation Revenues (2014 - 2016)
      •  
        $164.00 Included
    •  
      $93.00 Included

    • $93.00 Included

      • $93.00 Included
        •   Meridian Bioscience, Inc. Revenues (FY2014 - FT 2016)
      •  
        $93.00 Included
    •  
      $175.00 Included

    • $509.00 Included

      • $93.00 Included
        •   QIAGEN Revenues (2014, 2015, 2016)
      •  
        $484.00 Included
    •  
      $93.00 Included
    •  
      $93.00 Included

    • $171.00 Included

      • $93.00 Included
        •   Quidel Revenues (2014 - 2016)
      •  
        $159.00 Included
    •  
      $93.00 Included
    •  
      $134.00 Included

    • $188.00 Included

      • $93.00 Included
        •   Roche Revenues (2015 - 2016) (mCHF)
        •   Roche Revenues (2015 - 2016) (mUSD)
      •  
        $151.00 Included

    • $93.00 Included

      • $93.00 Included
        •   Siemens Revenues (2015 - 2016) (in millions of euros)
      •  
        $93.00 Included
    •  
      $104.00 Included
    •  
      $93.00 Included

    • $177.00 Included

      • $93.00 Included
        •   T2 Biosystems, Inc. Revenues (2014-2016)
      •  
        $170.00 Included

    • $114.00 Included

      • $93.00 Included
        •   Thermo Fisher Scientific Revenues (2014-2016)
      •  
        $97.00 Included

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.